Suven Life Sciences Limited — Board Meeting, 13-08-2025: Outcome of Board Meeting

Suven Life Sciences has announced its financial results for the quarter ended June 30, 2025. For the quarter, the company reported a consolidated net loss of ₹51.52 crore, with revenue from operations at ₹1.87 crore. A significant chunk of expenses, ₹41.49 crore, was directed towards R&D. On the funding front, the company received ₹291.66 crore as of June 30, 2025, from its preferential issue of convertible warrants. This includes the 25% upfront payment and the remaining 75% from two investors.